Background: Reports of hepatitis B virus (HBV) reactivation in solid tumors are very limited, and their frequencies and risk factors were previously unknown.
F I G U R E 1
Flow diagram of patient selection. This figure shows the flow diagram from assessment for eligibility to enrollment. HBV, hepatitis B virus; HBsAg, HBs antigen; HBcAb, anti-HBc antibody; HBsAb, anti-HBs antibody with solid tumors is recommended. 5 The cost of HBV-DNA monitoring is also a problem. 6 A consensus has not been reached regarding appropriate screening and monitoring.
In clinical practice, the HBV screening rate in Canada, the United States and Australia is as low as 14% to 19%. [6] [7] [8] In Japan, which is one of the HBV-endemic areas, 23.2% of the population has resolved HBV infection, 9 but the HBV screening rate is only 20.4%. 10 In patients with solid tumors with resolved HBV infection, it is necessary to identify a group with high risk and increase their screening rate to prevent de novo hepatitis B. Since 2012, our hospital has been conducting HBV screening in accordance with the Japanese de novo hepatitis B guidelines. 11 We conducted a retrospective study to evaluate the reactivation prevalence and risk factors in patients with resolved HBV infection. 
MATERIALS AND METHODS

Study population and design
Outcome and risk factor
The primary outcome of this study was determining the prevalence of HBV reactivation, which was measured as the percentage of patients with resolved HBV infection in whom HBV-DNA was reactivated. Risk factors for HBV reactivation were explored through analysis of a casecontrol study. Of 243 patients with resolved HBV infection, individuals in whom HBV-DNA was reactivated were considered patient cases and those in whom it was not reactivated were controls. Plasma HBV-DNA levels were determined with the TaqMan real-time polymerase 
Statistical analysis
The HBV reactivation prevalence was estimated as the number of HBV reactivation cases divided by the total number of patients with resolved HBV infection (negative for HBsAg and positive for HBcAb and/or positive for HBsAb). The 95% confidence interval (95% CI) of the HBV reactivation prevalence was calculated by the score test.
As a secondary endpoint, risk factors for HBV reactivation were evaluated by Pearson's 2 test. The significance level was set at P ≤ 0.05. In addition, 95% CIs were estimated by point estimation of the odds ratio and the score test. If the cell frequency was 0 in the two-way table, 0.5 was added to each cell, and, Pearson's 2 test was performed with a significance level of 5% on both sides.
In this study, because the outcome event was very rare, confounders were not adjusted for. In addition, because this study is exploratory, we did not adjust the multiplicity in the assessment of risk factors either.
All analysis of the background factors was performed using SPSS 24.0 (SPSS Inc., Chicago, IL, USA) and SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
Ethics
The study was done in accordance with the Declaration of Helsinki and the regulations of the Japanese Ministry of Health, Labor and Welfare.
The study protocol was approved by the ethics committee of Kobe City Medical Center General Hospital.
In this study, only data from daily clinical practice were collected and evaluated. Based on the Guidelines for Epidemiological Research, 12 we obtained consent by disclosing research information for opting-out. 
RESULTS
Background of patients with resolved HBV infection
Prevalence and details of HBV-DNA reactivation patients
HBV reactivation was found in five patients and the prevalence of the HBV-DNA reactivation was 2.1% (95% CI, 0.3-3.9%). In these patients (patients 1-5), we clearly observed the positive conversion of HBV-
TA B L E 1 Characteristics of 243 patients with resolved HBV infection
Characteristic
Total patients DNA during chemotherapy (Table 2 ). In addition, two other patients were positive for HBV-DNA. One patient was positive before starting chemotherapy (patient 6), and another patient was positive 3 months after starting chemotherapy. No measured data were available before starting chemotherapy for one patient (patient 7). The prevalence of HBV-DNA positivity was 2.9% (seven patients).
Two HBV-DNA-positive patients (patients 4 and 5) had quantifiable levels (≥1.3 log IU/mL) of HBV-DNA. In these patients, chemotherapy was discontinued and nucleic acid analogs were administered. We observed HBV-DNA negative conversion. The other five HBV-DNApositive patients (patients 1, 2, 3, 6 and 7) had unquantifiable levels (<1.3 log IU/mL). In these patients, we did not administer nucleic acid analogs to all the patients, and chemotherapy was continued in three patients (patients 1, 3 and 7). We did not observe any exacerbation of HBV-DNA. In the clinical course, "Stable" and "Better" mean no changed and decreased HBV-DNA levels, respectively. The average DEX dose per day was calculated as the total dexamethasone dose divided by the length of the chemotherapy duration in days. 
TA B L E 2 Details of seven HBV-DNA-positive patients
Risk factors for HBV reactivation
DISCUSSION
Reports of HBV reactivation and de novo hepatitis B in solid tumors are very limited, and their frequencies and risk factors were previously unknown. 13 This study enrolled 243 patients. To the best of our knowledge, this is the largest study to evaluate the risk factors in detail of cancer. 16 A low HBsAb titer may be due to a fragile immune response against HBV. Regarding the chemotherapy regimen, all patients with HBV reactivation had received chemotherapy containing platinum, which was not associated with HBV reactivation in this study. In the aforementioned study, there was no detectable association between immunosuppressants, such as methotrexate, and HBV reactivation in patients with rheumatoid arthritis. 15 In general, the intensity of chemotherapy for solid tumors may be lower than that for hematologic cancer. In this study, dexamethasone (≥1.0 mg/day) was a risk factor.
Preclinical studies have reported that steroids directly stimulate HBV replication and gene expression. 17, 18 Based on these findings, we speculate that the steroid dose is more likely than the chemotherapy regimen to be a factor in HBV reactivation in patients with solid tumors.
For chemotherapy regimens with a high or moderate emetic risk such as platinum-containing therapeutics, intermittent administration of 4-8 mg dexamethasone for 3-5 days during each cycle of the chemotherapy is recommended in each country's guidelines. [19] [20] [21] In other words, highly and moderately emetic chemotherapies are considered to be high risk for HBV reactivation from the results of this study.
In this study, the prevalence of HBV reactivation was extremely low in patients who did not have the above risk factors. However, some patients may be overlooked during HBV screening. Day et al. reported
that HBV screening for all patients before chemotherapy according F I G U R E 2 Odds ratio for HBV reactivation. The forest plot shows the odds ratios and 95% CIs of clinical parameters calculated by the 2 test for HBV reactivation. The proportion of patients in each reference group were 58.4% (≤70 years old, 48.6% (female), 51.0% (HBcAb ≥8.0 S/CO), 73.3% (HBsAb ≥15.0 mIU/mL), 33.7% (non-platinum regimen), 51.9% (total DEX ≤100 mg) and 32.5% (daily DEX dose ≤1.0 mg/day). HBsAg, HBs antigen; HBcAb, anti-HBc antibody; platinum, chemotherapy regimen containing platinum; DEX, dexamethasone; total DEX, the total DEX dose; daily DEX dose, calculated as the total dexamethasone dose divided by the length of the chemotherapy duration in days to current guidelines was not cost-effective for patients with solid tumors. 6 Therefore, targeted screening and monitoring should be considered. Reactivation was confirmed in a certain proportion of patients with low HBsAb titers and high doses of steroids. However, this study showed that appropriate screening and monitoring prevent the onset and severity of hepatitis.
This study had several limitations. First, information on HBV vaccination history was not obtained. In general, only HBsAb-positive patients are considered positive due to vaccination and are not at risk for HBV reactivation. However, because HBV reactivation has been reported in even these patients, 22, 23 we included such patients in HBV screening. HBV vaccination has not been incorporated into universal vaccination programs in Japan, and there are thought to be very few patients with a history of HBV vaccination in Japan. Second, it
was not possible to screen some patients before starting chemotherapy. Therefore, we cannot exclude the possibility that some patients became HBV positive before screening and subsequently became HBV negative. However, the period during which screening was delayed was short, and we believe that the likelihood of such patients progressing without any intervention was very low. Third, confounding factors may have influenced HBV reactivation, because this was a retrospective observational study and the incidence of HBV reactivation was small.
In conclusion, five patients (2.1%) showed reactivation of HBV-DNA, and no patients developed hepatitis due to early intervention.
We showed that HBsAb titer and average daily steroid dose were associated with HBV reactivation. In the future, risk factors that can identify targets for HBV screening must be determined by prospective studies.
